GlycoMimetics, Inc. (GLYC): Price and Financial Metrics

GlycoMimetics, Inc. (GLYC)

Today's Latest Price: $3.60 USD

0.05 (-1.37%)

Updated Nov 24 4:00pm

Add GLYC to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 389 in Biotech

See all "A" rated Strong Buy stocks

GLYC Stock Summary

  • For GLYC, its debt to operating expenses ratio is greater than that reported by only 8.06% of US equities we're observing.
  • GLYC's price/sales ratio is 17.51; that's higher than the P/S ratio of 90.86% of US stocks.
  • GLYC's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 8.89% of US stocks.
  • If you're looking for stocks that are quantitatively similar to Glycomimetics Inc, a group of peers worth examining would be CMRX, SGMO, SRRK, DTIL, and NXTC.
  • GLYC's SEC filings can be seen here. And to visit Glycomimetics Inc's official web site, go to

GLYC Stock Price Chart Interactive Chart >

Price chart for GLYC

GLYC Price/Volume Stats

Current price $3.60 52-week high $6.29
Prev. close $3.65 52-week low $1.82
Day low $3.54 Volume 1,167,600
Day high $3.86 Avg. volume 458,393
50-day MA $3.35 Dividend yield N/A
200-day MA $3.30 Market Cap 172.18M

GlycoMimetics, Inc. (GLYC) Company Bio

GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company is developing its lead product candidates include rivipansel, a pan-selectin antagonist, which is in Phase III clinical trials for the treatment of vaso-occlusive crisis, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease; and GMI-1271, an E-selectin antagonist to treat acute myeloid leukemia and other hematologic cancers. The company was founded in 2003 and is based in Rockville, Maryland.

GLYC Latest News Stream

Event/Time News Detail
Loading, please wait...

GLYC Latest Social Stream

Loading social stream, please wait...

View Full GLYC Social Stream

Latest GLYC News From Around the Web

Below are the latest news stories about Glycomimetics Inc that investors may wish to consider to help them evaluate GLYC as an investment opportunity.

GlycoMimetics to Present at Upcoming H.C. Wainwright & Co Annual Global Investment Virtual Conference

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Chief Executive Officer Rachel King will present at the upcoming H.C. Wainwright & Co 22nd Annual Global Investment Virtual Conference taking place September 14-16, 2020. The presentation will be available on the company’s website at the “Investors” tab for 30 days, beginning Monday, September 14 at 2:30 p.m. EDT. To access the live webcast and subsequent archived recordings for the presentation, please

Business Wire | September 8, 2020

GlycoMimetics, Inc. (GLYC) CEO Rachel King on Q2 2020 Results - Earnings Call Transcript

GlycoMimetics, Inc. (GLYC) Q2 2020 Earnings Conference Call July 31, 2020 08:30 AM ET Company Participants Shari Annes - Investor Relations Rachel King - Chief Executive Officer Brian Hahn - Senior Vice President and Chief Financial Officer Helen Thackray - Senior Vice President, Development and Chief Medical Officer Conference Call...

SA Transcripts on Seeking Alpha | August 1, 2020

GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2020

GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the second quarter ended June 30, 2020, and highlighted recent company events. Cash and cash equivalents at June 30, 2020 were $149.8 million.

Yahoo | July 31, 2020

GlycoMimetics to Report Second Quarter Financial Results on July 31, 2020

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will host a conference call and webcast to report its second quarter financial results on Friday, July 31, 2020, at 8:30 a.m. ET. The dial-in number for the conference call is (844) 413-7154 for domestic participants or (216) 562-0466 for international participants, with participant code 1677593. Participants are encouraged to connect 15 minutes in advance of the call to ensure that all callers are able

Business Wire | July 24, 2020

Here's Why We're Not Too Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Yahoo | July 22, 2020

Read More 'GLYC' Stories Here

GLYC Price Returns

1-mo 11.46%
3-mo -0.28%
6-mo 22.03%
1-year -34.78%
3-year -71.59%
5-year -47.21%
YTD -31.95%
2019 -44.14%
2018 -43.60%
2017 175.25%
2016 6.64%
2015 -20.56%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8807 seconds.